Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Terminated · Phase 1 · NCT03486067
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $1.3M
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 183
About the trial
- Sponsor
- Celgene
- Tested
- CC-93269 (drug)
- Dates
- Started 2018-04-03; completion 2025-03-18
- Results posted
- Not yet
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.
From ClinicalTrials.gov, last updated 2025-04-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Celgene Corporation reported $1.3M in research payments for this study in 2025 (6 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Luciano Costa Hematology & Oncology · Birmingham, AL
- Sandy W. Wong, M.D. Internal Medicine · San Francisco, CA
- Noffar Bar, M.D. Medical Oncology · New Haven, CT
- Craig C. Hofmeister, MD Hematology · Atlanta, GA
- Andrew J. Yee, MD Medical Oncology · Boston, MA
- Swathi Namburi, MD Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Lee Daeyeol Mms $605,393
- Dana Farber Cancer Institute, Inc $437,083
- Swedish Medical Center, WA $95,159
- Emory University Hospital, GA $47,362
- University of Alabama Hospital, AL $37,616
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $34,181
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.